These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Inhibition of aldehyde reductase by aldose reductase inhibitors. Sato S; Kador PF Biochem Pharmacol; 1990 Sep; 40(5):1033-42. PubMed ID: 2117925 [TBL] [Abstract][Full Text] [Related]
45. Effects of aldose reductase inhibition on the retina and health indices of streptozotocin-diabetic rats. Kozak WM; Marker NA; Elmer KK Doc Ophthalmol; 1986; 64(4):355-77. PubMed ID: 2958262 [TBL] [Abstract][Full Text] [Related]
46. Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: a light microscopic study. Datiles M; Fukui H; Kuwabara T; Kinoshita JH Invest Ophthalmol Vis Sci; 1982 Feb; 22(2):174-9. PubMed ID: 6799419 [TBL] [Abstract][Full Text] [Related]
47. Aldose reductase inhibitors and prevention of galactose cataracts in rats. Unakar N; Tsui J; Johnson M Invest Ophthalmol Vis Sci; 1989 Jul; 30(7):1623-32. PubMed ID: 2545646 [TBL] [Abstract][Full Text] [Related]
48. The effect of non-enzymatic glycation on recombinant human aldose reductase. Yamaoka T; Oda A; Bannai C; Itakura M; Yamashita K Diabetes Res Clin Pract; 1995 Mar; 27(3):165-9. PubMed ID: 7555597 [TBL] [Abstract][Full Text] [Related]
49. Effect of aldose reductase inhibitor (sorbinil) on integration of polyol pathway, pentose phosphate pathway, and glycolytic route in diabetic rat lens. Gonzalez AM; Sochor M; Hothersall JS; McLean P Diabetes; 1986 Nov; 35(11):1200-5. PubMed ID: 3093302 [TBL] [Abstract][Full Text] [Related]
50. Reversal of stage-I sugar cataract by Sorbinil, an aldose reductase inhibitor. Beyer-Mears A; Cruz E; Varagiannis E Pharmacology; 1985; 31(2):88-96. PubMed ID: 3927328 [TBL] [Abstract][Full Text] [Related]
51. Binding of an aldose reductase inhibitor to renal glomeruli. Cohen MP; Klepser H Biochem Biophys Res Commun; 1985 Jun; 129(2):530-5. PubMed ID: 3925947 [TBL] [Abstract][Full Text] [Related]
53. The effect of an aldose reductase inhibiting agent on limited joint mobility in diabetic patients. Eaton RP; Sibbitt WL; Harsh A JAMA; 1985 Mar; 253(10):1437-40. PubMed ID: 3918180 [TBL] [Abstract][Full Text] [Related]
54. The effects of glucose and an aldose reductase inhibitor on the sorbitol content and collagen synthesis of bovine retinal capillary pericytes in culture. Li W; Khatami M; Rockey JH Exp Eye Res; 1985 Mar; 40(3):439-44. PubMed ID: 3933992 [TBL] [Abstract][Full Text] [Related]
55. Effects of the aldose reductase inhibitor sorbinil on the isolated cultured rat lens. Yeh LA; Rafford CE; Beyer TA; Hutson NJ Metabolism; 1986 Apr; 35(4 Suppl 1):4-9. PubMed ID: 3083208 [TBL] [Abstract][Full Text] [Related]
56. Aldose reductase inhibition. The chemical key to the control of diabetic retinopathy? Frank RN Arch Ophthalmol; 1990 Sep; 108(9):1229-31. PubMed ID: 2119167 [No Abstract] [Full Text] [Related]
57. Noninvasive evaluation of effects of an aldose reductase inhibitor in rat brain by 19F FDG NMR spectroscopy. Nakada T; Kwee IL Magn Reson Med; 1987 Apr; 4(4):366-71. PubMed ID: 3108615 [TBL] [Abstract][Full Text] [Related]
58. Differences in the susceptibility of various aldose reductases to inhibition. II. Kador PF; Kinoshita JH; Tung WH; Chylack LT Invest Ophthalmol Vis Sci; 1980 Aug; 19(8):980-2. PubMed ID: 6773903 [TBL] [Abstract][Full Text] [Related]
59. Glomerular polyol accumulation in diabetes and its prevention by oral sorbinil. Beyer-Mears A; Ku L; Cohen MP Diabetes; 1984 Jun; 33(6):604-7. PubMed ID: 6427041 [TBL] [Abstract][Full Text] [Related]
60. The effect of aldose reductase inhibitor, statil, on hyperpermeability of iridial vessels in experimental galactosemic rats. Terubayashi H; Akagi Y Jpn J Ophthalmol; 1989; 33(3):343-7. PubMed ID: 2507812 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]